Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen Partners With FIRE-3 Researchers to Study microRNA Cancer Biomarker

NEW YORK (GenomeWeb) — IntegraGen announced today that it is collaborating with investigators from the FIRE-3 clinical trial to study the use of a microRNA biomarker to predict clinical outcomes in metastatic colorectal cancer patients treated with anti-EGFR therapies.

The FIRE-3 study is a Phase III trial comparing FOLFIRI — Camptosar (irinotecan) with fluorouracil and folinic acid — in combination with either Erbitux (cetuximab) or Avastin (bevacizumab) as a first-line therapy in patients with KRAS exon 2 wild-type stage IV colorectal cancer.

Through the collaboration, IntegraGen and the study investigators will test whether the expression levels of hsa-miR-31-3p in primary tumors can help determine how patients respond to the two treatment regimens.

About a year ago, Evry, France-based IntegraGen inked a similar deal to study the biomarker potential of hsa-miR-31-3p with researchers running a trial comparing other anti-EGFR therapy combinations in metastatic colorectal cancer patients.

The latest partnership "will allow us to further confirm that the miR-31-3p biomarker is predictive of effects of anti-EGFR therapy in wild-type KRAS patients with metastatic colorectal cancer," Francois Liebaert, IntegraGen's vice president of R&D and medical affairs, said in a statement.

"This collaboration with IntegraGen will permit us to further understand the differences in clinical outcomes we have reported for patients enrolled in the FIRE-3 study," Volker Heinemann, a researcher at the University Hospital Grosshadern and the trial's principal investigator, added in the statement. 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.